Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 234 participants.

Also called NCT06148649

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 234 participants (enrolled count) (from the registry)
Sponsor
Dongguan HEC Biopharmaceutical R&D Co., Ltd. (from the registry)
Registry
  • NCT NCT06148649
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06148649. Randomized; quadruple masking; primary purpose treatment. Start 2023-12-10 (actual); primary completion 2025-02-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus
Intervention (Drug)
HEC88473, Placebo, Dulaglutide
Lead sponsor
Dongguan HEC Biopharmaceutical R&D Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06148649
Content hash
ca7f1dd0e302dfd49ffcf2e44fe7978e3796ee970f84c18bb7d1842873e5758c